TAZVERIK®
(tazemetostat) tablets
200 mg

GETTING STARTED WITH TAZVERIK® (tazemetostat)

TAZVERIK is a prescription medicine used to treat:

- Adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, **and** who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure TAZVERIK is right for you.
- Adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

Important Safety Information

What is the most important information I should know about TAZVERIK?

TAZVERIK can cause serious side effects, including:

- **Risk of new cancers.** An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

Please see additional Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Medication Guide.

Your guide to treatment with TAZVERIK® (tazemetostat)

Your doctor may have prescribed or recommended TAZVERIK to help treat your follicular lymphoma. You may find it helpful for you and those involved in your care to learn more about your treatment and what to expect while taking TAZVERIK.

The information in this brochure is not meant to take the place of talking with your healthcare team. Always talk with your doctor if you have any questions about your treatment or side effects.

Selected Important Safety Information

Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.

- **Females** who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.
- **Males** with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.

Please see additional Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Medication Guide.

Table of Contents

You can also learn more at TAZVERIK.com/FL or call EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday through Friday (9 AM - 6 PM ET).

TAZVERIK® (tazemetostat) tablets 200 mg

What should I know about follicular lymphoma?

- Follicular lymphoma (FL) is a type of blood cancer.
- FL occurs when certain white blood cells, called *B-cell lymphocytes*, grow and multiply uncontrollably.
- These cancerous lymphocytes can travel to different parts of the body, such as the lymph nodes, spleen, bone marrow, and other organs.
- Although FL typically grows and spreads slowly, most people will eventually have progressive FL that requires multiple treatments.



What is "relapsed or refractory" FL?

You may hear your healthcare team refer to your cancer as being "relapsed" or "refractory." *Relapsed* means that your cancer came back after being treated. *Refractory* means that your cancer does not respond to treatment and cancer cells continue to grow.

Your healthcare team may decide to try a new treatment if you have relapsed or refractory FL. Depending on your unique situation, your doctor may recommend different treatment options.

What is TAZVERIK® (tazemetostat) and how does it work?

TAZVERIK is a prescription medicine used to treat:

- Adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, **and** who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure TAZVERIK is right for you.
- Adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

TAZVERIK is an oral, twice-daily treatment that works differently from other cancer treatments

- TAZVERIK is not a chemotherapy treatment and does not kill cancer cells directly.
- A protein called EZH2 helps regulate the development of B cells. When EZH2 is overactive, B cells do not develop correctly and continue to grow unchecked. This causes FL.
- Some people with FL may have an *EZH2 mutation*. This mutation may also lead to EZH2 being overactive, causing FL. Not everyone with FL has this mutation.
- TAZVERIK is the first type of therapy that was designed to target and block EZH2.

Selected Important Safety Information

Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK.

Please see additional Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Medication Guide.

TAZVERIK® (tazemetostat) tablets 200 mg

What were the results of the clinical study?

In cancer treatment studies, researchers want to know how many patients respond to therapy. This is measured as *overall response*, or the percentage of patients whose tumors either shrank by at least 50% or completely disappeared.

Every individual is different and may respond differently. In a clinical study that included patients with FL, with an EZH2 mutation (N=42) and without an EZH2 mutation (N=53):

69% of patients with an EZH2 mutation had an overall response* to TAZVERIK® (tazemetostat), including **12%** with a complete response† and **57%** with a partial response‡

34% of patients without an EZH2 mutation had an overall response* to TAZVERIK, including **4%** with a complete response† and **30%** with a partial response‡

Patients with an EZH2 mutation continued to respond to therapy for a median time§ of **10.9 months**
Range: 0.0+ to 22.1+ months



Patients without an EZH2 mutation continued to respond to therapy for a median time§ of **13.0 months**
Range: 1 to 22.5+ months





The time to achieve a response in the clinical trial ranged from:

- around 2 months to around 11 months for patients with an EZH2 mutation, with a median time§ of 3.7 months
- around 2 months to around 16 months for patients without an EZH2 mutation, with a median time§ of 3.9 months

*The overall response is the sum of partial responses and complete responses. It means the tumor either reduced in size by at least 50% or completely disappeared.
†Complete response=the tumor completely disappeared.
‡Partial response=the tumor reduced in size by at least 50%.
§The median is the middle number in a group. In other words, half the patients had a time above the median, and half the patients had a time below the median.

Selected Important Safety Information

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.

What should I avoid while taking TAZVERIK?
- Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.
- Avoid taking St. John's wort during treatment with TAZVERIK.

Talk to your healthcare provider before starting any new medications or supplements.

Please see additional Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Medication Guide.

TAZVERIK® (tazemetostat) tablets 200 mg

What are the possible side effects of TAZVERIK® (tazemetostat)?

It is important that you are informed about potential side effects during treatment with TAZVERIK. Talk to your doctor about concerns you may have.

TAZVERIK can cause serious side effects, including:

- **Risk of new cancers.** An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

The most common side effects of TAZVERIK in people with follicular lymphoma include:

- Tiredness
- Cold-like symptoms (upper respiratory infection)
- Bone and muscle pain
- Nausea
- Stomach (abdominal) pain

These are not all the possible side effects of TAZVERIK.
Call your doctor for medical advice and let them know when you experience side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Medication Guide.

What important information should I know before and while taking TAZVERIK?

Tell your healthcare provider about all your medical conditions, including if you:

- Are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.

Females who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.

Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.

- Are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.

TAZVERIK® (tazemetostat) tablets 200 mg

How do I take TAZVERIK® (tazemetostat)?

What is the recommended dose?

The recommended dosing is 4 tablets (200 mg each), twice daily. Your doctor will confirm what your dose should be, as some patients may need a different dose.

Tablets are not actual size.

What should I avoid while taking TAZVERIK?

- Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.
- Avoid taking St. John's wort during treatment with TAZVERIK.

Talk to your healthcare provider before starting any new medications or supplements.

How to take TAZVERIK

Take TAZVERIK exactly as your healthcare provider tells you.

Take TAZVERIK 2 times each day. Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with TAZVERIK if you experience certain side effects.

You can take TAZVERIK with or without food.

Each tablet should be swallowed whole. Do not cut, crush, or chew TAZVERIK tablets.

If you miss a dose or vomit after taking your dose, just skip that dose and take the next dose at your regular time.

It's important to keep your doctor informed of any changes during your treatment and to follow your prescribed treatment regimen.

Please see additional Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Medication Guide.

TAZVERIK® (tazemetostat) tablets 200 mg

EpizymeNOW Patient & Product Support

To help facilitate access to TAZVERIK® (tazemetostat) for patients with a valid prescription, EpizymeNOW Patient & Product Support can help you understand your insurance coverage and identify any financial or product support that may be available to you. Below is a list of support programs for which you may be eligible:

Quick Start Program:

You may be eligible to receive your medication right away if you:

- Experience a delay in the authorization of prescription drug coverage greater than five business days and
- Your doctor has determined there is an immediate medical need to start treatment with TAZVERIK

Patient Assistance Program (PAP):

You may be eligible to receive free medication if you are:

- Uninsured
- Underinsured (based on program eligibility criteria)
- Enrolled in the Medicare Part D benefit and have coverage for TAZVERIK, but are currently experiencing financial hardship (based on Epizyme's review of appropriate supporting documentation)

Bridge Supply Program:

You may be eligible to receive a limited supply of free medication if you experience an unexpected change or disruption in your prescription drug coverage or supply (e.g., your insurance provider requires a new or updated prior authorization or a change or loss of insurance).

Co-Pay Assistance Program:

For patients with commercial (private) health insurance, you may be eligible to receive co-payment assistance to help reduce your out-of-pocket costs for Epizyme medications.

This offer is not valid for cash-paying patients or patients currently enrolled in Medicare, Medicaid, or any other federal or state healthcare program. Limitations apply. Void where prohibited.

EpizymeNOW Patient & Product Support Eligibility Criteria

Quick Start & Bridge Supply	PAP	Co-Pay
You have prescription drug coverage either under a commercial (private) health plan or a government program, including Medicare or Medicaid, and you are actively pursuing initial coverage or reauthorization of coverage for TAZVERIK.	You meet Epizyme's financial eligibility requirements for enrollment in the Patient Assistance Program based on income and other supporting financial documentation.	You currently have commercial (private) health insurance that covers TAZVERIK and no primary or secondary insurance coverage under any state or federal healthcare program, including Medicare or Medicaid.
U.S. residency *(including U.S. territories)*		
You have a valid prescription for TAZVERIK		
Your insurance coverage for TAZVERIK is delayed for more than five business days, and your doctor has determined there is an immediate medical need to start treatment with TAZVERIK. If eligible, your 15-day supply (up to 60 days) of TAZVERIK will be provided to you until your prior authorization or coverage request for TAZVERIK is approved.	You are currently uninsured or underinsured based on insurance information verification by Epizyme.	

Disclaimer: All patient support is subject to eligibility criteria and program terms and conditions.

If you require any of the services mentioned above, ask your doctor for more information or contact EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday through Friday (9 AM - 6 PM ET).

Please see Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Medication Guide.

TAZVERIK® (tazemetostat) tablets 200 mg

Notes

Tip: Use these pages to list any questions for your healthcare team.

TAZVERIK®
(tazemetostat) tablets
200 mg

Additional Follicular Lymphoma Resources

While your healthcare team can provide support throughout your FL journey, there are other organizations and communities that may be able to help.

CancerCare

cancercare.org

1-800-813-HOPE (4673)

Lymphoma Research Foundation (LRF)

lymphoma.org

1-800-500-9976

The Leukemia & Lymphoma Society (LLS)

LLS.org

1-800-955-4572

Ongoing Support from EpizymeNOW

Talk to your doctor or visit TAZVERIK.com/FL to learn more. You can also contact EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday through Friday (9 AM - 6 PM ET).

TAZVERIK® (tazemetostat) tablets 200 mg